Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Aclasta er større end risiciene ved behandling af osteoporose hos mænd og postmenopausale kvinder med øget risiko for knoglebrud, herunder patienter, som for nylig har brækket hoften ved et mindre traume, samt til behandling af Pagets knoglesygdom.
The Committee for Medicinal Products for Human Use (CHMP) decided that Aclasta’ s benefits are greater than its risks for the treatment of osteoporosis in post-menopausal women and in men, at increased risk of fracture including those with a recent low-trauma hip fracture, and of Paget’ s disease of the bone.